Movember’s funding of game-changing programmes continues with announcement of a new research grant. Collaborating with the Irish Cancer Society, €1.75 million in funding will be dedicated to establish the first Irish Prostate Cancer Outcomes Research (IPCOR) in Ireland. This initiative will monitor, benchmark and publicly report annually on outcomes of prostate cancer treatment and care. This equates to €350,000 in funding being allocated per year, for up to five years.
The aim of IPCOR is to effectively record and report on outcomes of prostate cancer treatment and care with a view to improving the lives of those living with and beyond this disease. It aims to build on the National Cancer Registry data, by collecting data for all newly diagnosed prostate cancer cases in Ireland with the involvement of clinicians who treat men with prostate cancer. This will ultimately lead to better quality of treatment, care and survival for men diagnosed with prostate cancer in Ireland.
Professor John Fitzpatrick, Head of Research at the Irish Cancer Society said, “IPCOR will be the first Irish, quality clinical registry: funded by the Irish Cancer Society and Movember that will contain population-based, clinical and patient-reported data of men diagnosed with prostate cancer. This is significant because it will not only provide evidence-based data to clinicians, hospitals and decision makers on prostate cancer clinical practice, but it will also foster and evaluate improved quality of treatment and care for men newly diagnosed with prostate cancer.”
The main objectives of the Irish Prostate Cancer Outcomes Research (IPCOR) are:
- Monitor, benchmark and publicly report annually on the outcomes of prostate cancer treatment and care.
- Provide risk-adjusted, evidence-based data to clinicians, hospitals and decision makers on prostate cancer clinical practice that fosters and evaluates improved quality of treatment and care for men diagnosed with prostate cancer.
- Foster research leading to improvement in care and survival; ideally enabling comparisons across countries.
"Improving the physical and mental health of Irish men diagnosed and living with prostate cancer is a critical priority for Movember", said Neil Rooney, Movember's Irish Country Manager. "It’s an essential piece of research that will make a real difference to the lives of those affected by prostate cancer and we're proud that the Irish Movember community is able to help facilitate it. The research is testament to the communities’ ongoing support and fundraising which is driving innovative research that will have an everlasting impact on men's health in Ireland.”
.com_Carousel.jpg)
